NEO vs. RXRX, FUSN, TWST, SDGR, AGIO, ATEC, BTSG, SANA, SNDX, and DNA
Should you be buying NeoGenomics stock or one of its competitors? The main competitors of NeoGenomics include Recursion Pharmaceuticals (RXRX), Fusion Pharmaceuticals (FUSN), Twist Bioscience (TWST), Schrödinger (SDGR), Agios Pharmaceuticals (AGIO), Alphatec (ATEC), BrightSpring Health Services (BTSG), Sana Biotechnology (SANA), Syndax Pharmaceuticals (SNDX), and Ginkgo Bioworks (DNA). These companies are all part of the "medical" sector.
NeoGenomics (NASDAQ:NEO) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, dividends, community ranking, earnings, risk, valuation and profitability.
NeoGenomics received 471 more outperform votes than Recursion Pharmaceuticals when rated by MarketBeat users. Likewise, 70.44% of users gave NeoGenomics an outperform vote while only 50.00% of users gave Recursion Pharmaceuticals an outperform vote.
In the previous week, NeoGenomics had 1 more articles in the media than Recursion Pharmaceuticals. MarketBeat recorded 5 mentions for NeoGenomics and 4 mentions for Recursion Pharmaceuticals. NeoGenomics' average media sentiment score of 0.50 beat Recursion Pharmaceuticals' score of 0.14 indicating that NeoGenomics is being referred to more favorably in the media.
NeoGenomics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Recursion Pharmaceuticals has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500.
NeoGenomics has higher revenue and earnings than Recursion Pharmaceuticals. NeoGenomics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
NeoGenomics has a net margin of -14.87% compared to Recursion Pharmaceuticals' net margin of -735.99%. NeoGenomics' return on equity of -4.13% beat Recursion Pharmaceuticals' return on equity.
NeoGenomics currently has a consensus target price of $19.50, suggesting a potential upside of 37.91%. Recursion Pharmaceuticals has a consensus target price of $12.75, suggesting a potential upside of 57.02%. Given Recursion Pharmaceuticals' higher probable upside, analysts clearly believe Recursion Pharmaceuticals is more favorable than NeoGenomics.
98.5% of NeoGenomics shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 1.3% of NeoGenomics shares are owned by company insiders. Comparatively, 20.0% of Recursion Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
NeoGenomics beats Recursion Pharmaceuticals on 14 of the 18 factors compared between the two stocks.
Get NeoGenomics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NEO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
NeoGenomics Competitors List
Related Companies and Tools
